{"id":9885,"date":"2025-05-15T13:17:00","date_gmt":"2025-05-15T09:47:00","guid":{"rendered":"https:\/\/www.psvesta.com\/challenges-in-sourcing-pharmaceutical-raw-materials-in-the-global-market\/"},"modified":"2025-05-18T14:06:57","modified_gmt":"2025-05-18T10:36:57","slug":"challenges-in-sourcing-pharmaceutical-raw-materials-in-the-global-market","status":"publish","type":"post","link":"https:\/\/www.psvesta.com\/en\/challenges-in-sourcing-pharmaceutical-raw-materials-in-the-global-market\/","title":{"rendered":"Challenges in sourcing pharmaceutical raw materials in the global market"},"content":{"rendered":"

A hidden crisis in the health supply chain<\/em><\/p>\n

Introduction: The strategic importance of pharmaceutical raw materials <\/strong> (APIs)<\/strong><\/p>\n

Active Pharmaceutical Ingredients (APIs)<\/strong> are the backbone of the pharmaceutical industry. Without them, no pill, syrup, vaccine or injectable would be produced. But despite their vital importance, their sustainable supply in the global market faces serious and growing challenges. These challenges not only affect pharmaceutical companies, but also directly affect patient health and drug safety in countries. <\/p>\n

In this article, we will comprehensively examine the obstacles and challenges of the global pharmaceutical raw materials supply chain<\/strong> and their consequences.<\/p>\n

1<\/strong>. <\/strong>Strong global dependence on a small number of countries<\/strong><\/h4>\n

More than 70% of the pharmaceutical raw materials used in the world come from just a few specific countries \u2013 notably China and India.<\/strong> This intense concentration has made the global supply chain highly vulnerable to geopolitical disruptions, health and trade crises. <\/p>\n

Example<\/strong>:<\/strong><\/p>\n

During the COVID-19 outbreak, the nationwide lockdown in China halted the export of several vital raw materials, the shortages of which were immediately felt in many countries.<\/p>\n

2<\/strong>. <\/strong>Rising raw material prices and currency fluctuations<\/strong><\/h4>\n

One of the major challenges for pharmaceutical companies is the severe fluctuations in raw material prices<\/strong>, mainly due to reasons such as: <\/p>\n

    \n
  • Increasing energy prices (especially gas and electricity in chemical processes)<\/li>\n
  • Shortage of basic raw materials (such as solvents and intermediate compounds)<\/li>\n
  • Global shipping cost<\/li>\n
  • Exchange rate fluctuations, especially in countries with high pharmaceutical imports<\/li>\n<\/ul>\n

    It leads to a decrease in companies’ profit margins and an increase in the final price of the drug for the consumer.<\/p>\n

    3<\/strong>. <\/strong>Export restrictions and pharmaceutical nationalism<\/strong><\/h4>\n

    In times of crisis, such as pandemics or international tensions, many countries adopt nationalistic pharmaceutical<\/strong> policies and restrict or ban the export of raw materials. This directly affects countries that are pure importers. <\/p>\n

    Real example<\/strong>:<\/strong><\/p>\n

    In 2020, India temporarily suspended the export of more than 25 pharmaceutical raw materials, including paracetamol.<\/p>\n

    4<\/strong>. <\/strong>Environmental problems and legal restrictions<\/strong><\/h4>\n

    The production of many pharmaceutical raw materials is associated<\/strong> with high environmental pollution. This issue, especially in countries such as China and India, has led governments to require factories to comply with strict environmental regulations or even close some units. The result is a reduction in global production capacity and shortages in the market. <\/p>\n

    5<\/strong>. <\/strong>Quality and regulatory issues in the supply chain<\/strong><\/h4>\n

    With the transfer of production to low-cost countries, monitoring the quality<\/strong> of products sometimes comes with challenges. Examples include: <\/p>\n

      \n
    • Cross-contamination<\/li>\n
    • Non-compliance with GMP standards<\/li>\n
    • Adulteration or impurities in raw materials<\/li>\n<\/ul>\n

      All are public health threats.<\/p>\n

      6<\/strong>. <\/strong>Logistical complexities and international transportation<\/strong><\/h4>\n

      In the post-COVID-19 world, international shipping costs have skyrocketed, and delays in receiving raw materials have become a common problem for pharmaceutical companies. These delays cause production lines to stop, deliveries to pharmacies to be delayed, and even shortages at the hospital level. <\/p>\n

      7<\/strong>. <\/strong>Domestic challenges of countries in securing financial and foreign exchange resources<\/strong><\/h4>\n

      In developing countries or those with a limited exchange rate regime<\/strong>, securing foreign exchange to import raw materials is a major challenge. In addition, bureaucratic customs procedures also lead to delays in clearance and increase the final cost. <\/p>\n

      8<\/strong>. <\/strong>Lack of investment in local production<\/strong><\/h4>\n

      Many countries have relied on cheap imports from Asia for years and have therefore not invested enough in developing domestic infrastructure for API production. This has created a chronic dependency<\/strong> that will require time, technology, expertise and government support to overcome. <\/p>\n

      9<\/strong>. <\/strong>Intense competition and reduced profit margins for producers<\/strong><\/h4>\n

      In the global market, manufacturers drive prices down to the lowest possible level to gain market share<\/strong>. This intense competition sometimes drives out small players and leaves only a few suppliers, which reinforces monopoly. <\/p>\n

      10<\/strong>. <\/strong>Security risks and cyber attacks<\/strong><\/h4>\n

      Pharmaceutical supply chains have also been targeted by cyberattacks or digital disruptions. Disruptions to ordering systems, shipment tracking, or customs systems can disrupt the entire raw material supply process. <\/p>\n

      Solutions and suggestions for overcoming the raw material supply crisis<\/strong><\/h3>\n
        \n
      1. Diversifying supply sources<\/strong>
        \nReducing dependence on one or two specific countries<\/li>\n
      2. Investment in domestic <\/strong>API production<\/strong>
        \nGovernment support for pharmaceutical and raw material industries<\/li>\n
      3. Creating a national strategic stockpile<\/strong>
        \nMaintaining an acceptable volume of consumable raw materials in secure warehouses<\/li>\n
      4. Establishing regional partnerships<\/strong>
        \nCooperating with neighboring countries to produce and exchange pharmaceuticals<\/li>\n
      5. Supply Chain Digitization<\/strong>
        \nUsing Blockchain, Real-Time Tracking, and AI to Predict Shortages<\/li>\n<\/ol>\n

        Conclusion<\/strong><\/h4>\n

        The sustainable and high-quality supply of pharmaceutical raw materials in the global market faces numerous challenges rooted in economic, geopolitical, environmental, and technological factors. Overcoming this crisis requires long-term planning, targeted investment, resource diversification, and international cooperation.<\/strong> <\/p>\n

        Ultimately, a country that wants sustainable drug security must treat the raw materials supply chain as a national strategic priority.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

        A hidden crisis in the health supply chain Introduction: The strategic importance of pharmaceutical raw materials (APIs) Active Pharmaceutical Ingredients (APIs) are the backbone of the pharmaceutical industry. Without them, no pill, syrup, vaccine or injectable would be produced. But despite their vital importance, their sustainable supply in the global market faces serious and growing […]<\/p>\n","protected":false},"author":59,"featured_media":9880,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[427],"tags":[],"class_list":["post-9885","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-introduction-to-pharmaceutical-raw-materials-en"],"_links":{"self":[{"href":"https:\/\/www.psvesta.com\/en\/wp-json\/wp\/v2\/posts\/9885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.psvesta.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.psvesta.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.psvesta.com\/en\/wp-json\/wp\/v2\/users\/59"}],"replies":[{"embeddable":true,"href":"https:\/\/www.psvesta.com\/en\/wp-json\/wp\/v2\/comments?post=9885"}],"version-history":[{"count":1,"href":"https:\/\/www.psvesta.com\/en\/wp-json\/wp\/v2\/posts\/9885\/revisions"}],"predecessor-version":[{"id":9946,"href":"https:\/\/www.psvesta.com\/en\/wp-json\/wp\/v2\/posts\/9885\/revisions\/9946"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.psvesta.com\/en\/wp-json\/wp\/v2\/media\/9880"}],"wp:attachment":[{"href":"https:\/\/www.psvesta.com\/en\/wp-json\/wp\/v2\/media?parent=9885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.psvesta.com\/en\/wp-json\/wp\/v2\/categories?post=9885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.psvesta.com\/en\/wp-json\/wp\/v2\/tags?post=9885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}